Published in
Elsevier, Lancet Haematology, 11(4), p. e510-e523, 2017
DOI: 10.1016/s2352-3026(17)30174-6
Links
Tools
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial.
,
Paul La Rosée,
Mascha Binder,
Alberto Fabbri,
Valter Torri,
Eleonora Minacapelli,
Monica Falautano,
Fiorella Ilariucci,
Achille Ambrosetti,
Alexander Roth,
Claire Hemmaway
and other authors.
Full text: Unavailable
Abstract
Lymphoma Research Team ; The International Extranodal Lymphoma Study Group-32 (IELSG32) trial is an international randomised phase 2 study that addresses two key clinical questions in the treatment of patients with newly diagnosed primary CNS lymphoma. Results of the first randomisation have demonstrated that methotrexate, cytarabine, thiotepa, and rituximab (called the MATRix regimen) is the induction combination associated with significantly better outcome compared with the other induction combinations tested. Here, we report the results of the second randomisation that addresses the efficacy of myeloablative chemotherapy supported by autologous stem-cell transplantation (ASCT), as an alternative to whole-brain radiotherapy (WBRT), as consolidation after high-dose-methotrexate-based chemoimmunotherapy.